Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for DNL952 (Enzyme Replacement) in Late-Onset Pompe Disease. The expected timing is based on the latest available company guidance and may change.
01/29/26:- Ongoing Phase 1 Pompe study; study design and preclinical data to be presented at 2026 WORLDSymposium. 02/05/26:- WORLDSymposium update detailed Ph1 Pompe study design with multiple dose cohorts and preclinical glycogen reduction in muscle and brain. 02/26/26:- FDA lifted IND clinical hold in January 2026; Phase 1 Pompe study start-up activities underway. 05/07/26:- Phase 1 Pompe study start-up activities reiterated as underway; no new timeline shared. 08/06/26:- Ph1 dosing began in Q2 2026; initial clinical data expected in 2027.
Verification
Confirm timing and program details against the company announcement or filing.